Ordered Mesoporous Silica Delivering siRNA as Cancer Nanotherapeutics: A Comprehensive Review

Nanosized mesoporous silica has emerged as a promising flexible platform delivering siRNA for cancer treatment. This ordered mesoporous nanosized silica provides attractive features of well-defined and tunable porosity, structure, high payload, and multiple functionalizations for targeted delivery and increasing biocompatibility over other polymeric nanocarriers. Moreover, it also overcomes the lacunae associated with traditional administration of drugs. Chemically modified porous silica matrix efficiently entraps siRNA molecules and prevents their enzymatic degradation and premature release. This Review discusses the synthesis of silica using the sol-gel approach and the advantages with different silica mesostructure. Herein, the factors affecting the synthesis of silica at nanometer scale, shape, porosity and nanoparticle surface modification are also highlighted to attain the desired nanostructured silica carriers. Additional emphasis is given to chemically modified silica delivering siRNA, where the silica nanoparticle surface was modified with different chemical moieties such as amine modified with (3-aminoropyl) triethoxysilane, polyethylenimine, chitosan, poly(ethylene glycol), and cyclodextrin polymer modification to attain high therapeutic loading, improved dispersibility and biocompatibility. Upon systemic administration, ordered mesoporous nanosized silica encounters blood cells, immune cells, and organs mainly of the reticuloendothelial system (RES). Thereby, biocompatibility and biodistribution of silica based nanocarriers are deliberated to design principles for smart and efficacious nanostructured silica-siRNA carriers and their clinical trial status. This Review further reports the future scopes and challenges for developing silica nanomaterial as a promising siRNA delivery vehicle demanding FDA approval.

Electrochemical Chiral Recognition of Tryptophan Isomers Based on Nonionic Surfactant-Assisted Molecular Imprinting Sol-Gel Silica

A new molecularly imprinted SiO₂ (MISiO₂) film on the surface of indium tin oxide (ITO) electrode was prepared by the sol-gel method and was then applied successfully in the electrochemical chiral recognition of tryptophan (Trp) isomers. Owing to the high chemical stability, excellent rigidity, and low cost, the resultant sol-gel SiO₂ is a good matrix material for molecular imprinting. Nonionic surfactant cicosaethylene glycol hexadecyl ether (Brij58) arranged directionally on the surface of the hydrophobic ITO electrode possesses a large amount of oxygen-containing functional groups and may induce the accumulation of template molecules (L-Trp) on the surface of ITO, resulting in L-MISiO₂/ITO after the removal of L-Trp templates by calcination. The characterizations of the L-MISiO₂/ITO reveal that the L-Trp templates could be successfully removed from the matrix, producing complementary cavities within the L-MISiO₂/ITO. The resultant L-MISiO₂/ITO exhibits greatly higher affinity toward L-Trp than D-Trp due to the three-point interaction mechanism, and therefore it exhibits good chiral recognition ability for the Trp isomers. In addition, the as-prepared L-MISiO₂/ITO or D-MISiO₂/ITO (D-Trp as the templates) can predict the ratio of L- and D-isomers in racemic mixture. Last, the MISiO₂ films exhibited quick binding kinetics and good recognition reproducibility.

Electrospun Polyhydroxybutyrate/Poly(ε-caprolactone)/Sol-Gel-Derived Silica Hybrid Scaffolds with Drug Releasing Function for Bone Tissue Engineering Applications

Electrospun hybrid scaffolds are an effective platform to deliver drugs site specifically for the prevention and treatment of diseases in addition to promote tissue regeneration because of the flexibility to load drugs therein. In the present study, electrospun hybrid scaffolds containing antibiotics were developed to support cellular activities and eliminate potential postoperative inflammation and infection. As a model drug, levofloxacin (LFX) was successfully incorporated into pure polyhydroxybutyrate/poly(ε-caprolactone) (PHB/PCL) scaffolds and PHB/PCL/sol-gel-derived silica (SGS) scaffolds. The influence of LFX on the morphology, mechanical performance, chemical structure, drug release profile, and antibacterial effect of the scaffolds was thoroughly and comparatively investigated. MG-63 osteoblast-like cell cultivation on both scaffolds certified that LFX inclusion did not impair the biocompatibility. In addition to the favorable cellular proliferation and differentiation, scaffolds containing both LFX and SGS displayed highly increased mineralization content. Therefore, the present multifunctional hybrid scaffolds are promising in tissue engineering applications.